gene therapy News & Analysis
6 articles
Market Mood
Intellia (NTLA) Reports Phase 3 Results for HAE Gene Therapy
Intellia (NTLA) has presented Phase 3 results for its gene therapy, lonvo-z, aimed at treating hereditary angioedema (HAE). The data indicates significant improvements for patients, although specific numerical outcomes were not disclosed in the summary. The advancement in this clinical trial could enhance Intellia's market position and viability in the gene therapy space, impacting investor confidence. The results will likely influence future investments and strategies within the biotech sector.
Read More: Intellia (NTLA) Reports Phase 3 Results for HAE Gene Therapy
Eli Lilly (LLY) Stock Rating Reiterated Amid Gene Therapy Progress
Leerink has reiterated its stock rating for Eli Lilly (LLY), highlighting the company's ongoing advancements in gene therapy. Although specific data points or numerical targets were not disclosed in the article, the emphasis on progress suggests potential future benefits for LLY stock. The continuation of this rating indicates confidence among analysts regarding LLY's pipeline competitiveness and market position. Observers might consider this signal a bullish indicator for LLY's potential in the evolving biopharmaceutical sector.
Read More: Eli Lilly (LLY) Stock Rating Reiterated Amid Gene Therapy Progress
Regeneron (REGN) First-Quarter Earnings Show 19% Revenue Growth
Regeneron Pharmaceuticals (REGN) posted first-quarter revenue of $3.6 billion, a 19% increase year-over-year, surpassing analysts' expectations of $3.48 billion. Despite a 10% drop in Eylea sales to $941 million, Libtayo sales surged 54% to $438 million, and Dupixent sales reached $1.6 billion, up 36%. The company also initiated a new $3 billion share repurchase program following an $803 million buyback in Q1. Additionally, the FDA granted accelerated approval for Otarmeni, a gene therapy for hearing loss, further enhancing Regeneron's market potential.
Read More: Regeneron (REGN) First-Quarter Earnings Show 19% Revenue Growth
Regeneron (REGN) Offers Otarmeni Gene Therapy Free in U.S.
Regeneron Pharmaceuticals (REGN) announced its newly approved gene therapy, Otarmeni, will be offered for free in the U.S. while pricing in other countries is still undecided. CEO Leonard Schleifer indicated they are determining a fair price internationally. In clinical trials, 80% of participants saw hearing improvements, with estimates suggesting around 50 babies born annually in the U.S. with the condition. Analysts from Piper Sandler project peak sales of $130 million, emphasizing the limited financial impact due to the condition's rarity.
Read More: Regeneron (REGN) Offers Otarmeni Gene Therapy Free in U.S.
Regeneron (REGN) drug pricing deal lowers costs, offers free therapy
Regeneron (REGN) agreed to lower U.S. drug prices as part of a deal with President Trump, allowing for the first hearing-loss gene therapy to be offered for free to eligible U.S. patients following FDA approval. This agreement is part of a broader initiative involving 17 deals with pharmaceutical companies aimed at aligning U.S. drug prices with those in other developed nations. Regeneron's gene therapy, Otarmeni, has been projected to achieve peak sales of $130 million, offering significant potential market impact. The deal also includes a three-year exemption from tariffs on pharmaceutical products, which may influence pricing strategies.
Read More: Regeneron (REGN) drug pricing deal lowers costs, offers free therapy
Ultragenyx (RARE) BLA Accepted for Gene Therapy UX111 Approval
Ultragenyx (RARE) announced the FDA accepted its resubmitted Biologics License Application (BLA) for UX111, a gene therapy for Sanfilippo syndrome Type A, on April 2. The FDA has set a PDUFA action date of September 19 for a decision. If approved, UX111 would be the first treatment available for this genetic disorder. The therapy is designed to address the underlying enzyme deficiency causing significant health issues in affected children and has shown durable effects in clinical trials lasting up to 8 years.
Read More: Ultragenyx (RARE) BLA Accepted for Gene Therapy UX111 Approval